Business Context and Reporting Period
This Form 8-K was filed by Landec Corporation (not Lifecore Biomedical, Inc.) on January 20, 2022. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation matters.
Material Changes
- Board Expansion: The Board of Directors increased its size to 11 members.
- New Appointment: Ray Diradoorian was elected as a Class 2 Director and member of the Lifecore Focus Committee.
- Compensation Structure: Mr. Diradoorian will receive an annual cash retainer of $50,000 for Board service, plus additional amounts for committee service. He also received an annual restricted stock unit (RSU) award valued at $90,000, with a pro-rated initial grant of $30,000.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. No material risks or contingencies were disclosed in this specific report. The text confirms that Mr. Diradoorian has no material interest in any transaction exceeding $120,000 involving the Company.
Investor Verification Checklist
- Verify the registrant name is Landec Corporation (LNDC), not Lifecore Biomedical, Inc.
- Confirm the total Board size is now 11 members.
- Review the Definitive Proxy Statement filed on August 27, 2021, for full details on director compensation policies.
- Check for any subsequent filings regarding the vesting schedule of the $90,000 RSU award.